CN111743860B - Suspension medicine formula - Google Patents
Suspension medicine formula Download PDFInfo
- Publication number
- CN111743860B CN111743860B CN202010623793.8A CN202010623793A CN111743860B CN 111743860 B CN111743860 B CN 111743860B CN 202010623793 A CN202010623793 A CN 202010623793A CN 111743860 B CN111743860 B CN 111743860B
- Authority
- CN
- China
- Prior art keywords
- suspension
- sodium alginate
- solution
- iodoethersalicylamide
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/609—Amides, e.g. salicylamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
Abstract
The invention relates to the field of biological medicine, in particular to a suspension medicine formula which comprises iodoethersalicylamide, sodium alginate, an oil phase, a preservative, a surfactant and water. Sodium alginate is used as a thickening agent and a suspending agent in the formula, so that the time of layering of the iodothersalamide suspension can be delayed, and the technical problems that the iodothersalamide suspension is easy to precipitate and layer and the medicine is easy to harden after layering are solved. The scheme can be applied to practical activities such as preparation and production of the iodoethersalicylamide suspension.
Description
Technical Field
The invention relates to the field of biological medicine, in particular to a suspension medicine formula.
Background
The iohexosamine is called iohexol and N- (3 '-chloro-4' -p-chlorophenoxy-3, 5-diiodosalicyl) aniline, is an anthelmintic with antiplaque effect. The iodoethersalicylamide is a high-efficiency medicament for controlling adult and juvenile schistosomiasis of cattle and sheep liver fluke and fasciolopsis gigantea, and has good effects on blood-wool nematodes, fasciolopsis gigantea and maggots of sheep. The iodoethersalicylamide is a proton ionophore, can transport cations across cell membranes, has a decoupling effect on the mitochondrial oxidative phosphorylation process of the worm body, can reduce the generation of ATP, reduces the glycogen content, and accumulates succinic acid, thereby influencing the energy metabolic process of the worm body and leading the worm body to die. The iohexosamine is usually prepared into a suspension form for animals to take orally, but the iohexosamine cannot be stably dispersed in a suspension system, the iohexosamine suspension is easy to precipitate and layer after long-term storage, the medicine is easy to harden after layering, and the medicine is not easy to disperse again, so that the medicine effect is seriously influenced.
Disclosure of Invention
The invention aims to provide a suspension medicament formula, wherein sodium alginate is used as a thickening agent and a suspending agent in the formula, so that the time of layering of an iodothersalamide suspension can be delayed, and the technical problems that the iodothersalamide suspension is easy to precipitate and layer and the medicament is easy to harden after layering are solved.
In order to achieve the purpose, the invention adopts the following technical scheme:
a pharmaceutical formulation of suspension comprises iohexosamine and sodium alginate.
The principle and the advantages of the scheme are as follows: the iohersil is off-white to brown powder, is soluble in acetone, slightly soluble in chloroform or ethyl acetate, slightly soluble in methanol, and insoluble in water. The iohexosamine can not be stably dispersed in a suspension system, after long-term storage, the iohexosamine suspension is easy to precipitate and layer, the medicine is easy to harden after layering, and is not easy to disperse again, and the medicine effect is seriously influenced. After the sodium alginate absorbs water and swells, the viscosity of a dispersion medium can be increased so as to reduce the sedimentation speed of the iodoethersalicylamide particles. The sodium alginate is a natural polymer material, molecules of the sodium alginate are fully expanded in water after swelling, and groups on the molecules interact with the iodoethersalicylamide particles through intermolecular force, so that the iodoethersalicylamide can be uniformly dispersed in the aqueous solution of the sodium alginate. Sodium alginate can form a protective barrier of the iohexosamine, prevent or reduce attraction or flocculation between iohexosamine particles, and maintain a relatively uniform dispersion state of the iohexosamine particles.
The inventors have tried various suspending agents, such as sodium carboxymethylcellulose, xanthan gum, starch, polyethylene glycol, dextran, etc., which have not received a good suspending effect. By using the suspending agent, the suspension containing the iodoethersalicylamide still easily causes the phenomena of medicament precipitation delamination and medicament hardening after precipitation delamination. After various attempts, the inventor finds that the suspending agent sodium alginate has a very good effect on maintaining the stability of the iodoethersalicylamide suspension, and is far better than other types of suspending agents. Sodium alginate is used as a suspending agent, and the iodoethersalicylamide mixed suspension can be stably stored for a long time without layering. Even if the suspension is layered, the re-suspension of the iodoethersalicylamide can be achieved by gently shaking the vial. The inventor analyzes the reason that sodium alginate has a certain function of a surfactant, has good adaptability to the medicament of the iohexosamine, can reduce the surface tension of iohexosamine medicament particles, promotes the fusion of the medicament and an aqueous solution, increases the sedimentation volume ratio within a specified time, and prolongs the sedimentation time of the medicament.
Further, the mass ratio of the iodoethersalicylamide to the sodium alginate is 100:1-5: 1.
By adopting the technical scheme, the iodoethersalicylamide suspension with stable property can be compounded. The dosage of the sodium alginate is too low, and the suspension effect is weakened; the sodium alginate has high dosage and good suspension effect, but the liquid is too viscous and has poor fluidity, so that the use is inconvenient (the viscosity is too high and continuous administration can not be realized by a syringe), the suspension is also sticky to a bottle, and the medicament loss is too large. The iodoethersalicylamide and the sodium alginate are in an inverse relationship, and when the concentration of the iodoethersalicylamide is higher, the suspending agent dosage required for uniformly mixing the iodoethersalicylamide and the sodium alginate to form a suspension is reduced.
Furthermore, 1-10kg of iodoethersalicylamide is contained in each 100L of suspension medicine.
By adopting the technical scheme, sodium alginate is used as a suspending agent, so that stable suspension of the iodoethersalicylamide with the concentration is realized.
Further, the formula also comprises dimethyl silicone oil.
By adopting the technical scheme, the dimethicone can improve the surface activity of the sodium alginate, so that the iodoethersalicylamide can be stably suspended in the suspension.
Further, every 100L of the suspension medicine contains more than or equal to 7L of simethicone.
By adopting the technical scheme, the simethicone with the dosage can play a role in preventing the hardening of the suspension and enhancing the suspending effect of the sodium alginate on the iodoethersalicylamide.
Further, the formula also comprises vegetable oil, a preservative and a surfactant.
By adopting the technical scheme, the vegetable oil can partially replace the dimethyl silicone oil, so that the cost is reduced; the surfactant is a surfactant which has two opposite properties of lipophilicity and hydrophily in a molecule, and can reduce the surface tension of the drug particles, so that the iodoethersalicylamide particles can be fully wetted by water, can interact with a suspending agent and the like, and prevent the particles from settling and agglomerating. The suspension contains a large amount of oil phase and medicament, and if the oil phase can not be uniformly dispersed without using a surfactant, oil-water separation can be caused.
Further, the vegetable oil is one of soybean oil, sunflower seed oil, corn oil and rapeseed oil or mixed oil formed by more than two vegetable oils; the preservative is one or a mixture of more than two of benzyl alcohol, sorbic acid, benzoic acid, methyl paraben and ethyl paraben; the surfactant is a nonionic surfactant.
By adopting the technical scheme, the ionic surfactant can change a system charge system and destroy the original suspension system, so that the nonionic surfactant is required to be adopted.
Further, the formula consists of the iodoethersalicylamide, the sodium alginate, the soybean oil, the simethicone, the tween-80, the citric acid, the sodium citrate, the benzyl alcohol and the water.
By adopting the technical scheme, the suspension medicine with the formula has better stability, can be stored for a long time and does not cause the phenomenon of medicine hardening. Wherein, citric acid and sodium citrate are respectively flocculant and deflocculant, and can also play a role in adjusting and buffering pH value, and simultaneously, the citric acid and the sodium citrate can also be used as preservative of the suspension medicine.
Further, the suspension medicine is prepared by the following method: the suspension medicine is prepared by the following method: dispersing sodium alginate in water to obtain a sodium alginate solution; dissolving tween-80 in water to obtain tween solution; dispersing the iodoethersalicylamide in a tween solution, then adding the soybean oil, the simethicone and the benzyl alcohol, stirring uniformly, then adding the sodium alginate solution, and mixing uniformly again to obtain a mixed solution; adding a citric acid solution and a sodium citrate solution into the mixed solution, and then homogenizing the mixed solution under the pressure of 30 mpa; and adding water into the mixed solution after homogenization treatment to a set volume, and adjusting the pH value to 5.5-5.8 to obtain the suspension medicine.
By adopting the technical scheme, the sodium alginate is a high molecular material and needs to be dispersed in water and swelled; the iodoethersalicylamide is added into the tween-80 after the tween-80 is dissolved, otherwise, the medicament is not easy to disperse and wet and can float on the surface of the liquid; during the process of adding the oil phase (soybean oil and dimethyl silicone oil), the oil phase and the water phase are preferably added while stirring, so as to accelerate the uniform mixing of the oil phase and the water phase; the sodium alginate solution needs to be added at last, and because the sodium alginate has certain viscosity, the sodium alginate is added too early, and other components are not easy to be mixed uniformly. Among them, swelling is a phenomenon in which a high molecular polymer expands in volume in a solvent.
Further, the sodium alginate solution is prepared by the following method: dispersing sodium alginate in water, and standing at room temperature for 12h to obtain sodium alginate solution; or dispersing sodium alginate in 70-100 deg.C water, and standing in water for 2 hr to obtain sodium alginate solution.
By adopting the technical scheme, the sodium alginate is a high-molecular material, the swelling time of the sodium alginate needs to be ensured, and the sodium alginate can be used after being dissolved to form a uniform solution. If sodium alginate is not sufficiently swollen, its suspending effect is impaired.
Detailed Description
Example 1: preparation of iodoethersalicylamide suspension
The formula of the iodoethersalicylamide suspension is as follows: each 100L of suspension medicine contains 2kg of iodoethersalicylamide (oral grade, CAS NO.22662-39-1), 225g of sodium alginate (analytically pure, CAS NO.9005-38-3), 10kg of tween-80 (analytically pure, CAS NO.9005-65-6), 100g of citric acid (oral grade, CAS NO.77-92-9), 100g of sodium citrate (oral grade, CAS NO.68-04-2), 3L of soybean oil (food grade, CAS NO.8001-22-7), 7L of simethicone (food grade, CAS NO.9006-65-9), 1000ml of benzyl alcohol (analytically pure, CAS NO.100-51-6), and the balance of water (distilled water or water for injection). The sodium alginate used in the scheme is a high polymer material, and the viscosity of the sodium alginate needs to be checked according to the requirements of GB 1886.243-2016 national standard for food safety food additive sodium alginate, and the viscosity can be used in the formula within 600-800.
The preparation process of the iodoethersalicylamide suspension comprises the following steps (preparing 100L of suspension medicine):
1. dissolving sodium alginate in the formula amount with 20L of distilled water, and standing for 12h to swell the sodium alginate to obtain sodium alginate solution for use.
2. The tween-80 is dissolved in 20L of distilled water to obtain a tween solution for use (a nonionic surfactant is required, in this case, other nonionic surfactants can be used to replace tween-80, for example, the nonionic surfactant can be one or a mixture of more than two of poloxamer, tween-60 and tween-80).
3. Adding the iodoethersalicylamide with the formula amount into the Tween solution, uniformly stirring, adding the soybean oil, the simethicone and the benzyl alcohol with the formula amount, uniformly stirring, adding the sodium alginate solution, and uniformly stirring again to obtain a mixed solution.
4. And (3) dissolving citric acid and sodium citrate in distilled water respectively, adding the dissolved citric acid and sodium citrate into the mixed solution obtained in the step (3), and homogenizing twice by using a high-pressure homogenizer at the pressure of 30 mpa.
5. The iohexosamine suspension of this example was obtained by adding distilled water to approximately the full volume (100L) and adjusting the pH to 5.8 (generally, the pH was adjusted to 5.5-5.8, or optionally, the pH was not adjusted).
The mass ratio of the iohexosamine to the sodium alginate can be 100:1-2:1, but in order to control the viscosity (so that the fluidity of the suspension is better), the mass ratio of the iohexosamine to the sodium alginate is controlled to be 100:1-5: 1. In the scheme, 2kg of iodothersalamide and 225g of sodium alginate (namely 8.89:1) are specifically selected to be contained in each 100L of suspension medicine.
Example 2 is essentially the same as example 1, except that the formulation ingredients were changed (as shown in Table 1) and water swelling of sodium alginate at 70 deg.C for 2h was used in making the sodium alginate solution. Examples 3 to 5 are basically the same as example 1 except for the adjustment of the formulation and process parameters, as shown in Table 1.
Comparative examples 1 to 5 are substantially the same as in example 1, except for the adjustment of the formulation and process parameters, as shown in Table 2. In comparative examples 1 to 5, the amounts of the suspending agent (thickener) such as sodium carboxymethylcellulose, xanthan gum (dextran-70 complex), starch (dextran-20 complex), polyvinyl alcohol and dextran were all the optimum amounts obtained after many experimental tests.
Comparative example 6-comparative example 10 are substantially the same as example 1 except for the adjustment of the formulation and process parameters, as shown in table 3.
Comparative example 11 is substantially the same as example 1 except that after dispersing sodium alginate in water, there is no time left for the sodium alginate to swell and proceed directly to the next step. Comparative example 12 is substantially the same as example 1 except that the iodoethersalicylamide was dispersed in water to obtain an iodoethersalicylamide dispersion, tween-80 was added to the iodoethersalicylamide dispersion and stirred uniformly, then soybean oil, simethicone and benzyl alcohol in the formula amounts were added and stirred uniformly, then the sodium alginate solution was added and stirred uniformly again to obtain a mixed solution.
Table 1: example parameter setting conditions List (example 1-example 5)
Table 2: comparative example parameter setting case list (comparative example 1 to comparative example 5)
Table 3: comparative example parameter setting case list (comparative example 6-comparative example 10)
Experimental example 1
Sedimentation volume ratio: the sedimentation volume ratios of examples 1 to 5 and comparative examples 1 to 12 (10 replicates were set for each example or comparative example, n is 10) were measured by referring to the method for measuring the sedimentation volume ratio in 0111 oral solution, oral suspension and oral emulsion, first edition of chinese animal pharmacopoeia 2015, and the larger the sedimentation volume ratio for a given sedimentation time (3 h, 24h, 48h and 7 days, four sedimentation times are used in this experimental example), the better and more stable the suspension effect of the suspension is, and the experimental results are shown in tables 4 to 6.
And (3) detecting the redispersion condition: 500ml of the suspension in the above examples and comparative examples was taken, placed in a sample bottle (repeat experiment was not set), left to stand for three months (different degrees of delamination occurred in each case), and the sample bottle was inverted upside down, and it was observed how many times the delaminated suspension was inverted and re-dispersed, and the suspension was not re-dispersed even if the number of inversion exceeded 20 times, and the experiment results were as shown in tables 4 to 6, assuming that the sample was not re-dispersed.
Table 4: results of measurement (example 1 to example 5, sedimentation volume ratio is expressed in mean ± SD, n ═ 10)
Table 5: results of measurement (comparative examples 1 to 6, sedimentation volume ratio is expressed in mean ± SD, n ═ 10)
Table 6: results of measurement (comparative examples 7 to 12, sedimentation volume ratio is expressed in mean ± SD, n ═ 10)
According to the experimental results in tables 4 to 6, it can be known that the iohexosamine suspension obtained in examples 1 to 5 by adopting the formula and the preparation process of the scheme has better stability, sodium alginate has excellent suspension effect on iohexosamine, and the use of simethicone can promote the stability of the whole suspension and promote the redispersion of the suspension after delamination. The sedimentation volume ratios of the examples 1 to 5 at the respective sedimentation times are significantly different from those of the comparative examples 2 to 7 and 10 by statistical examination. In comparative examples 1 to 5, the inventors used different suspending agents (thickeners) to suspend the iohexosamine, and found that the above-mentioned treatment methods did not provide a good suspending effect, and that the iohexosamine-containing suspensions were still prone to drug precipitation delamination and drug hardening after precipitation delamination. Comparative example 6 reduced the amount of dimethicone, comparative example 7 and comparative example 8 did not use dimethicone, and comparative example 8 did not use sodium alginate. The result shows that the suspension effect is poor, and the suspension is easy to separate and not easy to redisperse due to the small dosage of the dimethyl silicone oil or no use of the dimethyl silicone oil. The sodium alginate and the dimethyl silicone oil are used in a matching way, so that the suspension effect on the medicine can be improved, and the medicine is easy to disperse again after being layered. In addition, comparative examples 1 and 8, in which sodium carboxymethylcellulose was used as a suspending agent, the sample liquid medicine was rapidly divided into three layers, the powder was solidified in a bean-flower shape, and the sedimentation volume ratio could not be measured (in the specific case: the suspension liquid medicine was divided into three layers, the powder and the oil phase floated on the upper layer, the powder layer on the lower layer, and the aqueous solution layer in the middle). The amount of sodium alginate used in comparative example 9 was too low, and the suspending effect was weak. Comparative example 10 used too high amount of sodium alginate, and the suspension was very good, but the liquid was too viscous and the fluidity was not good, which resulted in inconvenient use (too high viscosity for continuous administration by syringe), and also resulted in sticking of the suspension into a bottle and excessive loss of the drug. The iodoethersalicylamide and the sodium alginate are in an inverse relationship, and when the concentration of the iodoethersalicylamide is higher, the suspending agent dosage required for uniformly mixing the iodoethersalicylamide and the sodium alginate to form a suspension is reduced. The sodium alginate of comparative example 11 did not swell sufficiently, the suspending effect became poor, and the dispersion was not uniform. In comparative example 12, tween-80 was not first formulated into a solution before tween-80 and the drug were mixed. Thus, the drug is not easily dispersed and wetted and will float on the surface of the liquid.
The foregoing is merely an example of the present invention and common general knowledge of known specific structures and features of the embodiments is not described herein in any greater detail. It should be noted that, for those skilled in the art, without departing from the structure of the present invention, several changes and modifications can be made, which should also be regarded as the protection scope of the present invention, and these will not affect the effect of the implementation of the present invention and the practicability of the patent. The scope of the claims of the present application shall be determined by the contents of the claims, and the description of the embodiments and the like in the specification shall be used to explain the contents of the claims.
Claims (7)
1. A suspension medicine is characterized by comprising iodoethersalicylamide, sodium alginate, simethicone and tween-80; the mass ratio of the iodoethersalicylamide to the sodium alginate is 100:1-5: 1; 1-10kg of iodoethersalicylamide is contained in each 100L of suspension medicine;
in the process of preparing the suspension medicine, the mixing sequence of the iodoethersalicylamide, the sodium alginate and the tween-80 is as follows: dispersing and swelling sodium alginate in water to obtain a sodium alginate solution; dissolving tween-80 in water to obtain tween solution, and dispersing the iodoether salicylamide in the tween solution.
2. The suspension drug according to claim 1, characterized in that it contains 7L or more of simethicone per 100L of suspension drug.
3. The suspension drug of claim 2, further comprising a vegetable oil and a preservative.
4. A suspension drug according to claim 3, wherein said vegetable oil is one or a mixture of two or more of soybean oil, sunflower oil and corn oil; the preservative is one or a mixture of more than two of benzyl alcohol, sorbic acid, benzoic acid, methyl paraben and ethyl paraben.
5. A suspension medicament according to claim 4, wherein: it is composed of iodoethersalicylamide, sodium alginate, soybean oil, simethicone, tween-80, citric acid, sodium citrate, benzyl alcohol and water.
6. A suspension medicament according to claim 5, wherein: the suspension medicine is prepared by the following method: dispersing the iodoethersalicylamide in a tween solution, adding soybean oil, simethicone and benzyl alcohol, stirring uniformly, adding a sodium alginate solution, and mixing uniformly to obtain a mixed solution; adding a citric acid solution and a sodium citrate solution into the mixed solution, and then homogenizing the mixed solution under the pressure of 30 mpa; and adding water into the mixed solution after homogenization treatment to a set volume, and adjusting the pH value to 5.5-5.8 to obtain the suspension medicine.
7. A suspension medicament according to claim 6, wherein: the sodium alginate solution is prepared by the following method: dispersing sodium alginate in water, and standing at room temperature for 12h to obtain sodium alginate solution; or dispersing sodium alginate in 70-100 deg.C water, and standing in water for 2 hr to obtain sodium alginate solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010623793.8A CN111743860B (en) | 2020-06-30 | 2020-06-30 | Suspension medicine formula |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010623793.8A CN111743860B (en) | 2020-06-30 | 2020-06-30 | Suspension medicine formula |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111743860A CN111743860A (en) | 2020-10-09 |
| CN111743860B true CN111743860B (en) | 2022-04-05 |
Family
ID=72680349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010623793.8A Active CN111743860B (en) | 2020-06-30 | 2020-06-30 | Suspension medicine formula |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111743860B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3798258A (en) * | 1970-03-13 | 1974-03-19 | Merck & Co Inc | Salicylanilides |
| CN1375287A (en) * | 2001-03-16 | 2002-10-23 | 王玉万 | Veterinary mixed suspension injection containing chlorocyaniosaliamine or its sodium salt |
| CN105456260A (en) * | 2016-01-27 | 2016-04-06 | 成都乾坤动物药业有限公司 | Fenbendazole dry emulsion and preparation method thereof |
| WO2017157997A1 (en) * | 2016-03-16 | 2017-09-21 | Antibiotx Aps | Non-aqueous topical compositions comprising a halogenated salicylanilide |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108938563A (en) * | 2018-08-16 | 2018-12-07 | 重庆布尔动物药业有限公司 | A method of by the quickly dissolution/swelling of the water soluble polymer suspending agent in drug suspension |
-
2020
- 2020-06-30 CN CN202010623793.8A patent/CN111743860B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3798258A (en) * | 1970-03-13 | 1974-03-19 | Merck & Co Inc | Salicylanilides |
| CN1375287A (en) * | 2001-03-16 | 2002-10-23 | 王玉万 | Veterinary mixed suspension injection containing chlorocyaniosaliamine or its sodium salt |
| CN105456260A (en) * | 2016-01-27 | 2016-04-06 | 成都乾坤动物药业有限公司 | Fenbendazole dry emulsion and preparation method thereof |
| WO2017157997A1 (en) * | 2016-03-16 | 2017-09-21 | Antibiotx Aps | Non-aqueous topical compositions comprising a halogenated salicylanilide |
Non-Patent Citations (2)
| Title |
|---|
| 五氯柳胺阿苯达唑复方混悬液辅料相容性研究;李晓婷等;《畜牧与兽医》;20191231;第51卷(第6期);第57-62页 * |
| 碘醚柳胺的研制及其对肝片吸虫的驱虫试验;戴国华等;《中国兽药杂志》;19981231;第32卷(第2期);第1.3节 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111743860A (en) | 2020-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4569784A (en) | Preparation of a gel having gas transporting capability | |
| ES2716984T3 (en) | Seamless alginate capsules | |
| FI92149B (en) | A process for the preparation of a bunazosin-containing pharmaceutical preparation for transdermal administration | |
| CN104888224B (en) | A kind of amphiphilic polysaccharide derivative/poloxamer temperature sensitive type in-situ hydrogel and preparation method thereof | |
| US20090148529A1 (en) | Hydrogel Suspension and Manufacturing Process Thereof | |
| BR112019014985B1 (en) | STABLE COMPOSITION OF FAT-SOLUBLE ACTIVE INGREDIENT, MICROCAPSULE AND PROCESS OF PREPARATION AND USE OF THE SAME | |
| SE466130B (en) | GEL PHOTOGRAPHY LIQUID DIET FIBER COMPOSITION | |
| Villamagna et al. | Poly (ester amide) particles for controlled delivery of celecoxib | |
| CN104257632A (en) | Solid lipid nanometer particle for astaxanthin and preparation method of solid lipid nanometer particle | |
| CN111743860B (en) | Suspension medicine formula | |
| Wang et al. | Waxy maize starch nanoparticles incorporated tea polyphenols to stabilize Pickering emulsion and inhibit oil oxidation | |
| Torlopov et al. | Surface, rheopexy, digestive stability and toxicity of olive oil emulsions stabilized by chitin nanocrystals for vitamin D3 delivery | |
| CN111821260B (en) | Process for the manufacture of medicaments for suspension | |
| FI84230B (en) | FOERFARANDE FOER LADDNING AV VATTENSVAELLBARA, VATTENOLOESLIGA POLYMERER MED MEDROXIPROGESTERONACETAT. | |
| IL258608A (en) | Physically and chemically stable oral suspensions of givinostat | |
| CN115956668B (en) | Method for preparing high-stability Pickering emulsion based on cyclodextrin emulsification property regulation | |
| CN102485210B (en) | Voriconazole intravenous injection submicron emulsion and its preparation method | |
| CN111620956A (en) | Preparation method of starch caprylate and application of starch caprylate in pesticide microcapsule | |
| Almajidi et al. | Enhance solubility and prolong release of prochlorperazine maleate using floating nanoemulsion in situ gel | |
| US2742396A (en) | Ointment base | |
| CN105597101A (en) | Innovative pharmaceutic adjuvant colloidal microcrystalline cellulose and preparation method thereof | |
| BRPI0804639A2 (en) | A process for preparing a veterinary suspension formulation for administering a water-insoluble medicament by means of water delivery systems and their veterinary suspension formulation for administering a water-insoluble medicament | |
| ITTO20070479A1 (en) | VETERINARY COMPOSITION INJECTABLE TO ANTI-PROLACTINIC ACTIVITY | |
| WO2019227746A1 (en) | Chitosan oral solution and preparation method therefor | |
| CN113350282B (en) | Method for constructing acid-stable antioxidant quercetin targeted colloid delivery system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |